Successful treatment of prolonged COVID-19 with Bamlanivimab in a patient with severe B-Cell aplasia due to treatment with an anti-CD20 monoclonal antibody: A case report. (2021)

• Record Type: Journal Article
• Authors: Daher, Ayham; Müller, Tobias; Spiesshoefer, Jens; Dreher, Michael; Panse, Jens
• Is Part Of: Respiratory medicine case reports. Volume 34(2021)
• Publication Date: 2021
• Subjects: COVID-19 -- Immunodeficiency -- B-Cell aplasia -- Monoclonal antibodies; BMI body-mass index -- CRP C-reactive protein -- ICU intensive care unit -- IL-2 interleukin 2 -- CT computed tomography -- COVID-19 Coronavirus Disease 2019 -- NK natural killer -- SARS-CoV-2 severe acute respiratory syndrome coronavirus type 2 -- TNF-alpha Tumor necrosis factor; Respiratory organs -- Diseases -- Periodicals; Chest -- Diseases -- Periodicals; Respiratory Tract Diseases -- Periodicals; Respiratory System -- Periodicals; Chest -- Diseases; Respiratory organs -- Diseases; Electronic journals; Periodicals; 616.2
• DOI: 10.1016/j.rmcr.2021.101560
• Languages: English
• ISSNs: 2213-0071

Abstract

Abstract: A 71-year-old female patient with B-cell depletion due to treatment with an anti-CD20 monoclonal antibody was admitted for worsening COVID-19. Overall, she had persistent viral shedding, worsening respiratory failure, and progressive pneumonia that did not improve despite dexamethasone and antibiotic therapy. After administration of bamlanivimab, a monoclonal antibody with high affinity for the receptor-binding domain of the SARS-CoV-2 spike protein, inflammatory markers rapidly decreased, SARS-CoV2 RT-PCR became negative, and the patient improved clinically and radiologically. In conclusion, we demonstrated successful treatment of prolonged COVID-19 in a patient with severe B-cell aplasia with a virus-neutralizing monoclonal antibody.